[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Polatuzumab vedotin.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Tetracaine.]
[J01FA08, troleandomycin, The risk or severity of adverse effects can be increased when Troleandomycin is combined with Polatuzumab vedotin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Polatuzumab vedotin.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Ipilimumab is combined with Polatuzumab vedotin.]
[A10BH05, linagliptin, The metabolism of Polatuzumab vedotin can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The risk or severity of adverse effects can be increased when Boceprevir is combined with Polatuzumab vedotin.]
[J05AP02, telaprevir, The risk or severity of adverse effects can be increased when Telaprevir is combined with Polatuzumab vedotin.]
[C08DA01, verapamil, The metabolism of Polatuzumab vedotin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Polatuzumab vedotin can be decreased when combined with Viloxazine.]
[J05AE02, indinavir, The risk or severity of adverse effects can be increased when Indinavir is combined with Polatuzumab vedotin.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Polatuzumab vedotin.]
[L01ED01, crizotinib, The metabolism of Polatuzumab vedotin can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The metabolism of Polatuzumab vedotin can be decreased when combined with Ziprasidone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Polatuzumab vedotin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Polatuzumab vedotin.]
[J02AC03, voriconazole, The risk or severity of adverse effects can be increased when Voriconazole is combined with Polatuzumab vedotin.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Polatuzumab vedotin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Polatuzumab vedotin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Pertuzumab is combined with Polatuzumab vedotin.]
[V03AX03, cobicistat, The risk or severity of adverse effects can be increased when Cobicistat is combined with Polatuzumab vedotin.]
[J05AJ02, elvitegravir, The risk or severity of adverse effects can be increased when Elvitegravir is combined with Polatuzumab vedotin.]
[L02BB04, enzalutamide, The risk or severity of adverse effects can be decreased when Enzalutamide is combined with Polatuzumab vedotin.]
[J05AE04, nelfinavir, The risk or severity of adverse effects can be increased when Nelfinavir is combined with Polatuzumab vedotin.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Raxibacumab is combined with Polatuzumab vedotin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Benzocaine.]
[L01EC02, dabrafenib, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Benzyl alcohol.]
[J05AP05, simeprevir, The metabolism of Polatuzumab vedotin can be decreased when combined with Simeprevir.]
[A16AA07, metreleptin, The metabolism of Polatuzumab vedotin can be increased when combined with Metreleptin.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Polatuzumab vedotin.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Ramucirumab is combined with Polatuzumab vedotin.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Polatuzumab vedotin.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Polatuzumab vedotin.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Dulaglutide is combined with Polatuzumab vedotin.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Polatuzumab vedotin.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Nivolumab is combined with Polatuzumab vedotin.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Polatuzumab vedotin.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Alirocumab is combined with Polatuzumab vedotin.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Evolocumab is combined with Polatuzumab vedotin.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Idarucizumab is combined with Polatuzumab vedotin.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Polatuzumab vedotin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Polatuzumab vedotin.]
[J02AC05, isavuconazole, The metabolism of Polatuzumab vedotin can be decreased when combined with Isavuconazole.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Daratumumab is combined with Polatuzumab vedotin.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Necitumumab is combined with Polatuzumab vedotin.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Polatuzumab vedotin.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Polatuzumab vedotin.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ixekizumab is combined with Polatuzumab vedotin.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Reslizumab is combined with Polatuzumab vedotin.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Polatuzumab vedotin.]
[L01XX52, venetoclax, The metabolism of Polatuzumab vedotin can be decreased when combined with Venetoclax.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Atezolizumab is combined with Polatuzumab vedotin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Bupivacaine.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Olaratumab is combined with Polatuzumab vedotin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Brodalumab is combined with Polatuzumab vedotin.]
[L01EF02, ribociclib, The risk or severity of adverse effects can be increased when Ribociclib is combined with Polatuzumab vedotin.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Avelumab is combined with Polatuzumab vedotin.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Polatuzumab vedotin.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Dupilumab is combined with Polatuzumab vedotin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Polatuzumab vedotin.]
[J05AE09, tipranavir, The risk or severity of adverse effects can be increased when Tipranavir is combined with Polatuzumab vedotin.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Polatuzumab vedotin.]
[L01EX10, midostaurin, The risk or severity of adverse effects can be increased when Midostaurin is combined with Polatuzumab vedotin.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Durvalumab is combined with Polatuzumab vedotin.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Polatuzumab vedotin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Guselkumab is combined with Polatuzumab vedotin.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Polatuzumab vedotin.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Polatuzumab vedotin.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Polatuzumab vedotin.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Polatuzumab vedotin.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Benralizumab is combined with Polatuzumab vedotin.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emicizumab.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Capsaicin.]
[L02BB05, apalutamide, The risk or severity of adverse effects can be decreased when Apalutamide is combined with Polatuzumab vedotin.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be decreased when Carbamazepine is combined with Polatuzumab vedotin.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Burosumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Erenumab.]
[L01XX62, ivosidenib, The metabolism of Polatuzumab vedotin can be increased when combined with Ivosidenib.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Mogamulizumab.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Stiripentol is combined with Polatuzumab vedotin.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Galcanezumab.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emapalumab.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ravulizumab is combined with Polatuzumab vedotin.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Polatuzumab vedotin.]
[J01FA09, clarithromycin, The risk or severity of adverse effects can be increased when Clarithromycin is combined with Polatuzumab vedotin.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Romosozumab is combined with Polatuzumab vedotin.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Risankizumab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Polatuzumab vedotin.]
[S01AA13, fusidic acid, The metabolism of Polatuzumab vedotin can be decreased when combined with Fusidic acid.]
[N07XX11, pitolisant, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Pitolisant.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Brolucizumab.]
[L01FD01, trastuzumab, The risk or severity of adverse effects can be increased when Trastuzumab is combined with Polatuzumab vedotin.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Trastuzumab deruxtecan.]
[N03AX25, cenobamate, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Cenobamate.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Eptinezumab.]
[J05AE05, amprenavir, The risk or severity of adverse effects can be increased when Amprenavir is combined with Polatuzumab vedotin.]
[C01BD07, dronedarone, The metabolism of Polatuzumab vedotin can be decreased when combined with Dronedarone.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sacituzumab govitecan.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Polatuzumab vedotin.]
[L04AA47, inebilizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Dyclonine.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Satralizumab.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Polatuzumab vedotin.]
[B06AC06, berotralstat, The metabolism of Polatuzumab vedotin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The risk or severity of adverse effects can be increased when Lonafarnib is combined with Polatuzumab vedotin.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Margetuximab.]
[P03AX07, abametapir, The serum concentration of Polatuzumab vedotin can be increased when it is combined with Abametapir.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Polatuzumab vedotin.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Amivantamab.]
[L01XX73, sotorasib, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Sotorasib.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sotrovimab.]
[S03AA07, ciprofloxacin, The metabolism of Polatuzumab vedotin can be decreased when combined with Ciprofloxacin.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Aducanumab.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Anifrolumab is combined with Polatuzumab vedotin.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tisotumab vedotin.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be decreased when St. John's Wort is combined with Polatuzumab vedotin.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Tralokinumab is combined with Polatuzumab vedotin.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sutimlimab.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Levobupivacaine.]
[C01EB24, mavacamten, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Mavacamten.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Spesolimab.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Tremelimumab is combined with Polatuzumab vedotin.]
[N05AH02, clozapine, The metabolism of Polatuzumab vedotin can be decreased when combined with Clozapine.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Ublituximab is combined with Polatuzumab vedotin.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Polatuzumab vedotin.]
[H01AC08, somatrogon, The metabolism of Polatuzumab vedotin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Polatuzumab vedotin.]
[J01FA15, telithromycin, The risk or severity of adverse effects can be increased when Telithromycin is combined with Polatuzumab vedotin.]
[J02AC02, itraconazole, The risk or severity of adverse effects can be increased when Itraconazole is combined with Polatuzumab vedotin.]
[J02AC04, posaconazole, The risk or severity of adverse effects can be increased when Posaconazole is combined with Polatuzumab vedotin.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Polatuzumab vedotin.]
[S01XA18, cyclosporine, The metabolism of Polatuzumab vedotin can be decreased when combined with Cyclosporine.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Polatuzumab vedotin.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Polatuzumab vedotin.]
[G03XA01, danazol, The risk or severity of adverse effects can be increased when Danazol is combined with Polatuzumab vedotin.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Nefazodone is combined with Polatuzumab vedotin.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Polatuzumab vedotin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be decreased when Dexamethasone is combined with Polatuzumab vedotin.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Polatuzumab vedotin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Cinchocaine.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Polatuzumab vedotin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Polatuzumab vedotin.]
[C08CA03, isradipine, The metabolism of Polatuzumab vedotin can be decreased when combined with Isradipine.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Polatuzumab vedotin.]
[J05AE08, atazanavir, The risk or severity of adverse effects can be increased when Atazanavir is combined with Polatuzumab vedotin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Polatuzumab vedotin can be decreased when combined with Diltiazem.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Polatuzumab vedotin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Diphenhydramine.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Polatuzumab vedotin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Natalizumab is combined with Polatuzumab vedotin.]
[S02AA12, rifamycin SV, The risk or severity of adverse effects can be decreased when Rifamycin is combined with Polatuzumab vedotin.]
[J04AB05, rifapentine, The risk or severity of adverse effects can be decreased when Rifapentine is combined with Polatuzumab vedotin.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Polatuzumab vedotin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Ropivacaine.]
[A04AD12, aprepitant, The metabolism of Polatuzumab vedotin can be decreased when combined with Aprepitant.]
[G01AF05, econazole, The serum concentration of monomethyl auristatin E (MMAE), an active metabolite of Polatuzumab vedotin, can be increased when used in combination with Econazole.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Polatuzumab vedotin.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Polatuzumab vedotin.]
[C08CA12, mepirodipine, The metabolism of Polatuzumab vedotin can be decreased when combined with Barnidipine.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Polatuzumab vedotin.]
[S01AA17, erythromycin, The metabolism of Polatuzumab vedotin can be decreased when combined with Erythromycin.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Polatuzumab vedotin.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Polatuzumab vedotin.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Polatuzumab vedotin.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Polatuzumab vedotin.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Polatuzumab vedotin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Etidocaine.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Polatuzumab vedotin.]
[N06AB08, fluvoxamine, The metabolism of Polatuzumab vedotin can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Polatuzumab vedotin.]
[J02AC01, fluconazole, The metabolism of Polatuzumab vedotin can be decreased when combined with Fluconazole.]
[J05AE10, darunavir, The risk or severity of adverse effects can be increased when Darunavir is combined with Polatuzumab vedotin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Polatuzumab vedotin.]
[C08CA10, nilvadipine, The metabolism of Polatuzumab vedotin can be decreased when combined with Nilvadipine.]
[S01BA13, rimexolone, The serum concentration of monomethyl auristatin E (MMAE), an active metabolite of Polatuzumab vedotin, can be decreased when used in combination with Rimexolone.]
[N06AX17, milnacipran, The metabolism of Polatuzumab vedotin can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Polatuzumab vedotin.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Articaine.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Polatuzumab vedotin.]
[J04AC01, isoniazid, The metabolism of Polatuzumab vedotin can be decreased when combined with Isoniazid.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Polatuzumab vedotin.]
[J02AB02, ketoconazole, The risk or severity of adverse effects can be increased when Ketoconazole is combined with Polatuzumab vedotin.]
[H02CA04, levoketoconazole, The risk or severity of adverse effects can be increased when Levoketoconazole is combined with Polatuzumab vedotin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Lidocaine.]
[C10AA02, lovastatin, The metabolism of Polatuzumab vedotin can be decreased when combined with Lovastatin.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Nilotinib is combined with Polatuzumab vedotin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Mepivacaine.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Polatuzumab vedotin.]
[S02AA13, miconazole, The metabolism of Polatuzumab vedotin can be decreased when combined with Miconazole.]
[L01XX23, mitotane, The risk or severity of adverse effects can be decreased when Mitotane is combined with Polatuzumab vedotin.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Polatuzumab vedotin.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Polatuzumab vedotin.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Polatuzumab vedotin.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be decreased when Fosphenytoin is combined with Polatuzumab vedotin.]
[V03AB15, naloxone, The risk or severity of adverse effects can be increased when Naloxone is combined with Polatuzumab vedotin.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Polatuzumab vedotin.]
[N06AX23, desvenlafaxine, The metabolism of Polatuzumab vedotin can be decreased when combined with Desvenlafaxine.]
[C08CA04, nicardipine, The metabolism of Polatuzumab vedotin can be decreased when combined with Nicardipine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be decreased when Pentobarbital is combined with Polatuzumab vedotin.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Edrecolomab.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be decreased when Phenobarbital is combined with Polatuzumab vedotin.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be decreased when Phenytoin is combined with Polatuzumab vedotin.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Polatuzumab vedotin.]
[J05AE01, saquinavir, The risk or severity of adverse effects can be increased when Saquinavir is combined with Polatuzumab vedotin.]
[J05AG02, delavirdine, The risk or severity of adverse effects can be increased when Delavirdine is combined with Polatuzumab vedotin.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Polatuzumab vedotin.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Ustekinumab is combined with Polatuzumab vedotin.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Polatuzumab vedotin.]
[J05AE03, ritonavir, The risk or severity of adverse effects can be increased when Ritonavir is combined with Polatuzumab vedotin.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Polatuzumab vedotin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of adverse effects can be decreased when Primidone is combined with Polatuzumab vedotin.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Procaine.]
[J04AB02, rifampin, The risk or severity of adverse effects can be decreased when Rifampicin is combined with Polatuzumab vedotin.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Polatuzumab vedotin.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Polatuzumab vedotin.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Polatuzumab vedotin.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Polatuzumab vedotin.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Tetracaine.]
[J01FA08, troleandomycin, The risk or severity of adverse effects can be increased when Troleandomycin is combined with Polatuzumab vedotin.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Belimumab is combined with Polatuzumab vedotin.]
[L01FX04, ipilimumab, The risk or severity of adverse effects can be increased when Ipilimumab is combined with Polatuzumab vedotin.]
[A10BH05, linagliptin, The metabolism of Polatuzumab vedotin can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The risk or severity of adverse effects can be increased when Boceprevir is combined with Polatuzumab vedotin.]
[J05AP02, telaprevir, The risk or severity of adverse effects can be increased when Telaprevir is combined with Polatuzumab vedotin.]
[C08DA01, verapamil, The metabolism of Polatuzumab vedotin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Polatuzumab vedotin can be decreased when combined with Viloxazine.]
[J05AE02, indinavir, The risk or severity of adverse effects can be increased when Indinavir is combined with Polatuzumab vedotin.]
[L01FX05, brentuximab vedotin, The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Polatuzumab vedotin.]
[L01ED01, crizotinib, The metabolism of Polatuzumab vedotin can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The metabolism of Polatuzumab vedotin can be decreased when combined with Ziprasidone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Polatuzumab vedotin.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Polatuzumab vedotin.]
[J02AC03, voriconazole, The risk or severity of adverse effects can be increased when Voriconazole is combined with Polatuzumab vedotin.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Polatuzumab vedotin.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Polatuzumab vedotin.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Polatuzumab vedotin.]
[L01FD02, pertuzumab, The risk or severity of adverse effects can be increased when Pertuzumab is combined with Polatuzumab vedotin.]
[V03AX03, cobicistat, The risk or severity of adverse effects can be increased when Cobicistat is combined with Polatuzumab vedotin.]
[J05AJ02, elvitegravir, The risk or severity of adverse effects can be increased when Elvitegravir is combined with Polatuzumab vedotin.]
[L02BB04, enzalutamide, The risk or severity of adverse effects can be decreased when Enzalutamide is combined with Polatuzumab vedotin.]
[J05AE04, nelfinavir, The risk or severity of adverse effects can be increased when Nelfinavir is combined with Polatuzumab vedotin.]
[J06BC02, raxibacumab, The risk or severity of adverse effects can be increased when Raxibacumab is combined with Polatuzumab vedotin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Benzocaine.]
[L01EC02, dabrafenib, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Benzyl alcohol.]
[J05AP05, simeprevir, The metabolism of Polatuzumab vedotin can be decreased when combined with Simeprevir.]
[A16AA07, metreleptin, The metabolism of Polatuzumab vedotin can be increased when combined with Metreleptin.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Siltuximab is combined with Polatuzumab vedotin.]
[L01FG02, ramucirumab, The risk or severity of adverse effects can be increased when Ramucirumab is combined with Polatuzumab vedotin.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Vedolizumab is combined with Polatuzumab vedotin.]
[L01FF02, pembrolizumab, The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Polatuzumab vedotin.]
[A10BJ05, dulaglutide, The risk or severity of adverse effects can be increased when Dulaglutide is combined with Polatuzumab vedotin.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Blinatumomab is combined with Polatuzumab vedotin.]
[L01FF01, nivolumab, The risk or severity of adverse effects can be increased when Nivolumab is combined with Polatuzumab vedotin.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Secukinumab is combined with Polatuzumab vedotin.]
[C10AX14, alirocumab, The risk or severity of adverse effects can be increased when Alirocumab is combined with Polatuzumab vedotin.]
[C10AX13, evolocumab, The risk or severity of adverse effects can be increased when Evolocumab is combined with Polatuzumab vedotin.]
[V03AB37, idarucizumab, The risk or severity of adverse effects can be increased when Idarucizumab is combined with Polatuzumab vedotin.]
[A16AB13, asfotase alfa, The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Polatuzumab vedotin.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Mepolizumab is combined with Polatuzumab vedotin.]
[J02AC05, isavuconazole, The metabolism of Polatuzumab vedotin can be decreased when combined with Isavuconazole.]
[L01FC01, daratumumab, The risk or severity of adverse effects can be increased when Daratumumab is combined with Polatuzumab vedotin.]
[L01FE03, necitumumab, The risk or severity of adverse effects can be increased when Necitumumab is combined with Polatuzumab vedotin.]
[L01FX08, elotuzumab, The risk or severity of adverse effects can be increased when Elotuzumab is combined with Polatuzumab vedotin.]
[J06BB02, tetanus immune globulin, The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Polatuzumab vedotin.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Ixekizumab is combined with Polatuzumab vedotin.]
[R03DX08, reslizumab, The risk or severity of adverse effects can be increased when Reslizumab is combined with Polatuzumab vedotin.]
[J06BC04, obiltoxaximab, The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Polatuzumab vedotin.]
[L01XX52, venetoclax, The metabolism of Polatuzumab vedotin can be decreased when combined with Venetoclax.]
[L01FF05, atezolizumab, The risk or severity of adverse effects can be increased when Atezolizumab is combined with Polatuzumab vedotin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Bupivacaine.]
[J06BC03, bezlotoxumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bezlotoxumab.]
[L01FX10, olaratumab, The risk or severity of adverse effects can be increased when Olaratumab is combined with Polatuzumab vedotin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Brodalumab is combined with Polatuzumab vedotin.]
[L01EF02, ribociclib, The risk or severity of adverse effects can be increased when Ribociclib is combined with Polatuzumab vedotin.]
[L01FF04, avelumab, The risk or severity of adverse effects can be increased when Avelumab is combined with Polatuzumab vedotin.]
[L04AA36, ocrelizumab, The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Polatuzumab vedotin.]
[D11AH05, dupilumab, The risk or severity of adverse effects can be increased when Dupilumab is combined with Polatuzumab vedotin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Oxybuprocaine.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Polatuzumab vedotin.]
[J05AE09, tipranavir, The risk or severity of adverse effects can be increased when Tipranavir is combined with Polatuzumab vedotin.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Polatuzumab vedotin.]
[L01EX10, midostaurin, The risk or severity of adverse effects can be increased when Midostaurin is combined with Polatuzumab vedotin.]
[L01FF03, durvalumab, The risk or severity of adverse effects can be increased when Durvalumab is combined with Polatuzumab vedotin.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Sarilumab is combined with Polatuzumab vedotin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Guselkumab is combined with Polatuzumab vedotin.]
[J06BD01, palivizumab, The risk or severity of adverse effects can be increased when Palivizumab is combined with Polatuzumab vedotin.]
[L01FB01, inotuzumab ozogamicin, The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Polatuzumab vedotin.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Polatuzumab vedotin.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Polatuzumab vedotin.]
[R03DX10, benralizumab, The risk or severity of adverse effects can be increased when Benralizumab is combined with Polatuzumab vedotin.]
[B02BX06, emicizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emicizumab.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Capsaicin.]
[L02BB05, apalutamide, The risk or severity of adverse effects can be decreased when Apalutamide is combined with Polatuzumab vedotin.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be decreased when Carbamazepine is combined with Polatuzumab vedotin.]
[J05AX23, ibalizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ibalizumab.]
[M05BX05, burosumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Burosumab.]
[N02CD01, erenumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Erenumab.]
[L01XX62, ivosidenib, The metabolism of Polatuzumab vedotin can be increased when combined with Ivosidenib.]
[L04AC17, tildrakizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tildrakizumab.]
[L01FX09, mogamulizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Mogamulizumab.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Stiripentol is combined with Polatuzumab vedotin.]
[B06AC05, lanadelumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Lanadelumab.]
[N02CD03, fremanezumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Fremanezumab.]
[L01FF06, cemiplimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Cemiplimab.]
[N02CD02, galcanezumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Galcanezumab.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Chloroprocaine.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emapalumab.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Ravulizumab is combined with Polatuzumab vedotin.]
[B01AX07, caplacizumab, The risk or severity of adverse effects can be increased when Caplacizumab is combined with Polatuzumab vedotin.]
[J01FA09, clarithromycin, The risk or severity of adverse effects can be increased when Clarithromycin is combined with Polatuzumab vedotin.]
[M05BX06, romosozumab, The risk or severity of adverse effects can be increased when Romosozumab is combined with Polatuzumab vedotin.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Risankizumab.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Polatuzumab vedotin.]
[S01AA13, fusidic acid, The metabolism of Polatuzumab vedotin can be decreased when combined with Fusidic acid.]
[N07XX11, pitolisant, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Pitolisant.]
[S01LA06, brolucizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Brolucizumab.]
[L01FD01, trastuzumab, The risk or severity of adverse effects can be increased when Trastuzumab is combined with Polatuzumab vedotin.]
[L01FD04, trastuzumab deruxtecan, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Trastuzumab deruxtecan.]
[N03AX25, cenobamate, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Cenobamate.]
[L01FC02, isatuximab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Isatuximab.]
[N02CD05, eptinezumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Eptinezumab.]
[J05AE05, amprenavir, The risk or severity of adverse effects can be increased when Amprenavir is combined with Polatuzumab vedotin.]
[C01BD07, dronedarone, The metabolism of Polatuzumab vedotin can be decreased when combined with Dronedarone.]
[L01FX17, sacituzumab govitecan, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sacituzumab govitecan.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Polatuzumab vedotin.]
[L04AA47, inebilizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Dyclonine.]
[L01FX12, tafasitamab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tafasitamab.]
[L01FX15, belantamab mafodotin, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Satralizumab.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the thrombogenic activities of Polatuzumab vedotin.]
[B06AC06, berotralstat, The metabolism of Polatuzumab vedotin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The risk or severity of adverse effects can be increased when Lonafarnib is combined with Polatuzumab vedotin.]
[J06BD04, ansuvimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Ansuvimab.]
[L01FD06, margetuximab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Margetuximab.]
[P03AX07, abametapir, The serum concentration of Polatuzumab vedotin can be increased when it is combined with Abametapir.]
[S01LA08, bevacizumab, The risk or severity of adverse effects can be increased when Bevacizumab is combined with Polatuzumab vedotin.]
[L01FF07, dostarlimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Dostarlimab.]
[L01FX22, loncastuximab tesirine, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Loncastuximab tesirine.]
[L01FX18, amivantamab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Amivantamab.]
[L01XX73, sotorasib, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Sotorasib.]
[J06BD05, sotrovimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sotrovimab.]
[S03AA07, ciprofloxacin, The metabolism of Polatuzumab vedotin can be decreased when combined with Ciprofloxacin.]
[N06DX03, aducanumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Aducanumab.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Anifrolumab is combined with Polatuzumab vedotin.]
[L01FX23, tisotumab vedotin, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tisotumab vedotin.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be decreased when St. John's Wort is combined with Polatuzumab vedotin.]
[R03DX11, tezepelumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tezepelumab.]
[D11AH07, tralokinumab, The risk or severity of adverse effects can be increased when Tralokinumab is combined with Polatuzumab vedotin.]
[L04AA55, sutimlimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sutimlimab.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Levobupivacaine.]
[C01EB24, mavacamten, The serum concentration of Polatuzumab vedotin can be decreased when it is combined with Mavacamten.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Spesolimab.]
[L01FX20, tremelimumab, The risk or severity of adverse effects can be increased when Tremelimumab is combined with Polatuzumab vedotin.]
[N05AH02, clozapine, The metabolism of Polatuzumab vedotin can be decreased when combined with Clozapine.]
[L04AA57, ublituximab, The risk or severity of adverse effects can be increased when Ublituximab is combined with Polatuzumab vedotin.]
[L01FE02, panitumumab, The risk or severity of adverse effects can be increased when Panitumumab is combined with Polatuzumab vedotin.]
[H01AC08, somatrogon, The metabolism of Polatuzumab vedotin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bimekizumab.]
[J06BB04, hepatitis B immune globulin, The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Polatuzumab vedotin.]
[J01FA15, telithromycin, The risk or severity of adverse effects can be increased when Telithromycin is combined with Polatuzumab vedotin.]
[J02AC02, itraconazole, The risk or severity of adverse effects can be increased when Itraconazole is combined with Polatuzumab vedotin.]
[J02AC04, posaconazole, The risk or severity of adverse effects can be increased when Posaconazole is combined with Polatuzumab vedotin.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Polatuzumab vedotin.]
[S01XA18, cyclosporine, The metabolism of Polatuzumab vedotin can be decreased when combined with Cyclosporine.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Conivaptan is combined with Polatuzumab vedotin.]
[R03DX05, omalizumab, The risk or severity of adverse effects can be increased when Omalizumab is combined with Polatuzumab vedotin.]
[G03XA01, danazol, The risk or severity of adverse effects can be increased when Danazol is combined with Polatuzumab vedotin.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Nefazodone is combined with Polatuzumab vedotin.]
[L01FE01, cetuximab, The risk or severity of adverse effects can be increased when Cetuximab is combined with Polatuzumab vedotin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be decreased when Dexamethasone is combined with Polatuzumab vedotin.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Polatuzumab vedotin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Cinchocaine.]
[G03CC02, dienestrol, Dienestrol may increase the thrombogenic activities of Polatuzumab vedotin.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the thrombogenic activities of Polatuzumab vedotin.]
[C08CA03, isradipine, The metabolism of Polatuzumab vedotin can be decreased when combined with Isradipine.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the thrombogenic activities of Polatuzumab vedotin.]
[J05AE08, atazanavir, The risk or severity of adverse effects can be increased when Atazanavir is combined with Polatuzumab vedotin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Polatuzumab vedotin can be decreased when combined with Diltiazem.]
[G03CA09, promestriene, Promestriene may increase the thrombogenic activities of Polatuzumab vedotin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Diphenhydramine.]
[J06BB01, Rho(D) immune globulin, The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Polatuzumab vedotin.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Natalizumab is combined with Polatuzumab vedotin.]
[S02AA12, rifamycin SV, The risk or severity of adverse effects can be decreased when Rifamycin is combined with Polatuzumab vedotin.]
[J04AB05, rifapentine, The risk or severity of adverse effects can be decreased when Rifapentine is combined with Polatuzumab vedotin.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Polatuzumab vedotin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Ropivacaine.]
[A04AD12, aprepitant, The metabolism of Polatuzumab vedotin can be decreased when combined with Aprepitant.]
[G01AF05, econazole, The serum concentration of monomethyl auristatin E (MMAE), an active metabolite of Polatuzumab vedotin, can be increased when used in combination with Econazole.]
[G03CX01, tibolone, Tibolone may increase the thrombogenic activities of Polatuzumab vedotin.]
[J06BB03, varicella-zoster immune globulin, The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Polatuzumab vedotin.]
[C08CA12, mepirodipine, The metabolism of Polatuzumab vedotin can be decreased when combined with Barnidipine.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Polatuzumab vedotin.]
[S01AA17, erythromycin, The metabolism of Polatuzumab vedotin can be decreased when combined with Erythromycin.]
[G03CA03, estradiol, Estradiol may increase the thrombogenic activities of Polatuzumab vedotin.]
[G03CC06, estriol, Estriol may increase the thrombogenic activities of Polatuzumab vedotin.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may increase the thrombogenic activities of Polatuzumab vedotin.]
[G03CC04, estrone, Estrone may increase the thrombogenic activities of Polatuzumab vedotin.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the thrombogenic activities of Polatuzumab vedotin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Etidocaine.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Polatuzumab vedotin.]
[N06AB08, fluvoxamine, The metabolism of Polatuzumab vedotin can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Polatuzumab vedotin.]
[J02AC01, fluconazole, The metabolism of Polatuzumab vedotin can be decreased when combined with Fluconazole.]
[J05AE10, darunavir, The risk or severity of adverse effects can be increased when Darunavir is combined with Polatuzumab vedotin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Polatuzumab vedotin.]
[C08CA10, nilvadipine, The metabolism of Polatuzumab vedotin can be decreased when combined with Nilvadipine.]
[S01BA13, rimexolone, The serum concentration of monomethyl auristatin E (MMAE), an active metabolite of Polatuzumab vedotin, can be decreased when used in combination with Rimexolone.]
[N06AX17, milnacipran, The metabolism of Polatuzumab vedotin can be decreased when combined with Milnacipran.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Eculizumab is combined with Polatuzumab vedotin.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Articaine.]
[S01LA04, ranibizumab, The risk or severity of adverse effects can be increased when Ranibizumab is combined with Polatuzumab vedotin.]
[J04AC01, isoniazid, The metabolism of Polatuzumab vedotin can be decreased when combined with Isoniazid.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Tocilizumab is combined with Polatuzumab vedotin.]
[J02AB02, ketoconazole, The risk or severity of adverse effects can be increased when Ketoconazole is combined with Polatuzumab vedotin.]
[H02CA04, levoketoconazole, The risk or severity of adverse effects can be increased when Levoketoconazole is combined with Polatuzumab vedotin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Lidocaine.]
[C10AA02, lovastatin, The metabolism of Polatuzumab vedotin can be decreased when combined with Lovastatin.]
[L01EA03, nilotinib, The risk or severity of adverse effects can be increased when Nilotinib is combined with Polatuzumab vedotin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Mepivacaine.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Polatuzumab vedotin.]
[S02AA13, miconazole, The metabolism of Polatuzumab vedotin can be decreased when combined with Miconazole.]
[L01XX23, mitotane, The risk or severity of adverse effects can be decreased when Mitotane is combined with Polatuzumab vedotin.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Polatuzumab vedotin.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Polatuzumab vedotin.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Ofatumumab is combined with Polatuzumab vedotin.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be decreased when Fosphenytoin is combined with Polatuzumab vedotin.]
[V03AB15, naloxone, The risk or severity of adverse effects can be increased when Naloxone is combined with Polatuzumab vedotin.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Polatuzumab vedotin.]
[N06AX23, desvenlafaxine, The metabolism of Polatuzumab vedotin can be decreased when combined with Desvenlafaxine.]
[C08CA04, nicardipine, The metabolism of Polatuzumab vedotin can be decreased when combined with Nicardipine.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be decreased when Pentobarbital is combined with Polatuzumab vedotin.]
[L01FX01, edrecolomab, The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Edrecolomab.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be decreased when Phenobarbital is combined with Polatuzumab vedotin.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be decreased when Phenytoin is combined with Polatuzumab vedotin.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Golimumab is combined with Polatuzumab vedotin.]
[J05AE01, saquinavir, The risk or severity of adverse effects can be increased when Saquinavir is combined with Polatuzumab vedotin.]
[J05AG02, delavirdine, The risk or severity of adverse effects can be increased when Delavirdine is combined with Polatuzumab vedotin.]
[B01AC13, abciximab, The risk or severity of adverse effects can be increased when Abciximab is combined with Polatuzumab vedotin.]
[L04AC05, ustekinumab, The risk or severity of adverse effects can be increased when Ustekinumab is combined with Polatuzumab vedotin.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Canakinumab is combined with Polatuzumab vedotin.]
[J05AE03, ritonavir, The risk or severity of adverse effects can be increased when Ritonavir is combined with Polatuzumab vedotin.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Polatuzumab vedotin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The risk or severity of adverse effects can be decreased when Primidone is combined with Polatuzumab vedotin.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Polatuzumab vedotin is combined with Procaine.]
[J04AB02, rifampin, The risk or severity of adverse effects can be decreased when Rifampicin is combined with Polatuzumab vedotin.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Polatuzumab vedotin.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Polatuzumab vedotin.]
[L01FD03, ado-trastuzumab emtansine, The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Polatuzumab vedotin.]
